SMi’s 2nd annual Ophthalmic Drugs conference returning to London, takes place at the Copthorne Tara Hotel in Kensington, on the 26th – 27th November 2018.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.
Building on last year’s success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive, half-day post-conference workshops on 28th November 2018, led by twoXAR and Aston University
This Year’s Agenda Highlights Include:
Chairs for 2018:
View the full agenda online: www.ophthalmicdrugs.com/pnhq
Social Media Handles
ophthalmic drug development, ophthalmic, ophthalmology, vision, diabetic retinopathy, ocular diseases, medical devices, nanotechnology, drug delivery, glaucoma, AMD, optical, optic, optometrist, ophthalmologist, eye, eyecare, visual, diabetes
Additional Contact Info:
T: +44 (0)20 7827 6048
© 2018 PHARMA NEWS HQ, All rights reserved
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.